State Street Corp Has $3.18 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

State Street Corp grew its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 5.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 952,912 shares of the company’s stock after buying an additional 53,051 shares during the period. State Street Corp owned 1.24% of Trevi Therapeutics worth $3,183,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets increased its position in Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares during the period. Hsbc Holdings PLC bought a new stake in Trevi Therapeutics during the second quarter valued at $61,000. Intech Investment Management LLC acquired a new stake in Trevi Therapeutics during the third quarter worth approximately $63,000. The Manufacturers Life Insurance Company increased its holdings in Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Trevi Therapeutics in the third quarter valued at approximately $78,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Trading Down 4.0 %

Shares of TRVI stock opened at $4.10 on Tuesday. Trevi Therapeutics, Inc. has a 12 month low of $1.27 and a 12 month high of $4.68. The stock has a market capitalization of $315.15 million, a P/E ratio of -9.32 and a beta of 0.96. The firm’s 50 day moving average is $3.22 and its 200 day moving average is $3.05.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the prior year, the firm posted ($0.08) earnings per share. On average, equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TRVI shares. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, December 12th. Leerink Partners started coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. HC Wainwright upped their price objective on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a report on Thursday, December 12th. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $9.31.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.